Patient‐reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis

Stauder, Reinhard; Lambert, Jérémy; Desruol‐Allardin, Sandra; Savre, Isabelle; Gaugler, Lona; Stojkov, Igor; Siebert, Uwe; Chevrou‐Séverac, Hélène

doi:10.1111/ejh.13389

Cited by 27 publications

(28 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, little attention has been paid to the effects on HRQoL in patients diagnosed with haematological cancer [ 9 - 13 ]. Life expectancy in patients with haematological cancer is generally increased and sometimes is now close to that observed in the general population for all ages [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Health Related Quality of Life in Patients with Onco-hematological Diseases

Nasa¹,

Caocci²,

Morelli³

et al. 2020

CPEMH

View full text Add to dashboard Cite

Background: HRQoL is generally conceptualized as a broad multidimensional construct that refers to patients' perceptions of the impact of disease and its treatment on their physical, psychological, and social functioning and well-being. Little is known in patients with onco-hematological cancer in comparison with the general population and other chronic diseases. Objective: We assessed HRQoL in patients diagnosed with haematological cancers in comparison with the general population and other chronic diseases. Methods: The questionnaire Short Form (SF)-12 was administered to 62 patients with onco-hematological disease and results were compared with 702 controls (184 healthy people, 37 Major Depression, 201 Multiple Sclerosis; 23 Wilson disease; 46 Carotidal Atherosclerosis; 60 Celiac disease; 151 solid tumours). Results: HRQoL in patients diagnosed with a haematological cancer was significantly worse in comparison with the general population (F= 43.853, p <0.00001) but similar when compared with solid tumour and other chronic diseases such as Major Depression and Carotid Atherosclerosis. In addition, HRQoL in patients diagnosed with a haematological cancer was significantly higher than that due to Celiac disease (p <0.00001) and Wilson's disease (p= 0.02), and lower than that due to Multiple Sclerosis (p= 0.032). Conclusion: This study confirmed that haematological cancers negatively affects overall HRQoL. The results showed an impact of haematological cancers on HRQoL that is similar to what found in patients with solid tumors, Major Depression and Carotid Atherosclerosis. Current successful therapeutic strategy achieved in the treatment of haematological cancers not only positively impact on survival rate but also could improve the overall HRQoL.

show abstract

Section: Introductionmentioning

confidence: 99%

Health Related Quality of Life in Patients with Onco-hematological Diseases

Nasa¹,

Caocci²,

Morelli³

et al. 2020

CPEMH

View full text Add to dashboard Cite

show abstract

Section: Acute Myeloid Leukemia (Aml)mentioning

confidence: 99%

“…Patients with AML experience a wide range of symptoms. This is due to the immense heterogeneity of the disease, resulting from diverse gene mutations and chromosomal abnormalities, making the clinical management of AML very challenging ( Stauder et al 2020 ). The most treatable form of AML is acute promyelocytic leukemia (APL), a highly curable disease by treatment with arsenic trioxide and all-trans retinoic acid ( Swords et al 2016 ).…”

Section: Acute Leukemiasmentioning

confidence: 99%

Blood cancer health disparities in the United States Hispanic population

Bencomo‐Alvarez

Rubio

Gonzalez

et al. 2021

Cold Spring Harb Mol Case Stud

View full text Add to dashboard Cite

Cancer is a challenging, multifaceted disease that involves a combination of biological and non-biological factors. Aside from COVID-19, cancer is the second leading cause of death in the United States (U.S.), and the first among Hispanic Americans. The Hispanic population is the largest minority group in the U.S., which is rapidly growing in size. Unfortunately, U.S. Hispanics and other minority groups experience many different health disparities, resulting in poor survival outcomes and a reduced quality of life. Factors such as genomic mutations, lower socioeconomic status, lack of education, reduced access to health care, comorbidities, and environmental factors all contribute to these health care inequalities. In the context of blood cancer health disparities, Hispanic patients are often diagnosed at a younger age and have worse outcomes compared with non-Hispanic individuals. In the present article, we highlight the existing knowledge about cancer health disparities in the Hispanic population, with a focus on chronic and acute leukemia. In our experience at the U.S./Mexico border, analysis of several different blood cancers demonstrated that younger Hispanic patients with acute lymphoid or myeloid leukemia have higher incidence rates and worse prognoses. A combined approach, involving improved health care access and better knowledge of the underlying factors, will allow for more timely diagnoses and the development of intervention strategies aimed at reducing or eliminating the disparities.

show abstract

“…76 It is, therefore, highly relevant that future studies address the association between geriatric impairments and PROMS. 77 In addition to clinical judgment and treatment allocation, a geriatric assessment can be used to introduce non-oncological interventions before and during treatment in the hope of improving the patient's health status, resilience and treatment tolerance. However, evidence concerning the effectiveness of such non-oncological interventions is limited.…”

Section: Publicationmentioning

confidence: 99%